| Literature DB >> 29713636 |
Olga Krupkova1,2, Lucas Smolders1, Karin Wuertz-Kozak2,3,4,5, James Cook6, Antonio Pozzi1.
Abstract
Serious knee pain and related disability have an annual prevalence of approximately 25% on those over the age of 55 years. As curative treatments for the common knee problems are not available to date, knee pathologies typically progress and often lead to osteoarthritis (OA). While the roles that the meniscus plays in knee biomechanics are well characterized, biological mechanisms underlying meniscus pathophysiology and roles in knee pain and OA progression are not fully clear. Experimental treatments for knee disorders that are successful in animal models often produce unsatisfactory results in humans due to species differences or the inability to fully replicate disease progression in experimental animals. The use of animals with spontaneous knee pathologies, such as dogs, can significantly help addressing this issue. As microscopic and macroscopic anatomy of the canine and human menisci are similar, spontaneous meniscal pathologies in canine patients are thought to be highly relevant for translational medicine. However, it is not clear whether the biomolecular mechanisms of pain, degradation of extracellular matrix, and inflammatory responses are species dependent. The aims of this review are (1) to provide an overview of the anatomy, physiology, and pathology of the human and canine meniscus, (2) to compare the known signaling pathways involved in spontaneous meniscus pathology between both species, and (3) to assess the relevance of dogs with spontaneous meniscal pathology as a translational model. Understanding these mechanisms in human and canine meniscus can help to advance diagnostic and therapeutic strategies for painful knee disorders and improve clinical decision making.Entities:
Keywords: dog; inflammation; meniscus; oxidative stress; pain
Year: 2018 PMID: 29713636 PMCID: PMC5911564 DOI: 10.3389/fvets.2018.00073
Source DB: PubMed Journal: Front Vet Sci ISSN: 2297-1769
Characteristics of experimental canine models for meniscal pathologies.
| Model | Trigger | Meniscal damage | Resulting OA | Synovial inflammation | Reference |
|---|---|---|---|---|---|
| Cranial cruciate ligament/anterior cruciate ligament transection | Joint instability | Secondary | Moderate to severe | Yes | ( |
| Meniscal release | Joint instability | Primary | Moderate to severe | Yes | ( |
| Meniscectomy | Joint instability | Removal | Related to the size of the preserved meniscus | Yes | ( |
| Cartilage grooving | Chondral damage | Secondary | Mild | Yes | ( |
Figure 1Meniscal tears in dogs. (A) Grossly normal meniscus with outerbridge grade 1 cartilage pathology; (B) grossly normal meniscus with outerbridge grade 2 cartilage pathology; (C) displaced bucket handle tear; (D) acute complex tears without gross evidence of degeneration; (E) complex tears with gross evidence of degeneration; (F) outerbridge grade 4 of both femoral and tibial articular surface associated with meniscal tear.
Figure 2(A) A degenerative meniscal tear characterized by fibrillation, softening, and discoloration. (B) An horizontal cleavage tear is apparent when probing the mid-substance of the meniscus after performing a partial meniscectomy.
Possible therapeutic targets in menisci and SF associated with aging and degenerative knee/stifle disorders.
| Therapeutic targets | Type of dysregulation | Found in human | Found in dog | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Extracellular matrix (ECM) constituents | Glycosaminoglycans | Degradation | M: unchanged | M: unchanged ( | ||||||
| Collagens | Degradation | M: reduced ( | M: uk | |||||||
| ECM remodeling | ADAMTS4 | Overexpression/activity | M: yes ( | M: uk | ||||||
| ADAMTS5 | Overexpression/activity | M: uk | M: uk | |||||||
| MMP1 | Overexpression/activity | M: yes ( | M: uk | |||||||
| MMP2 | Overexpression/activity | M: yes ( | M: uk | |||||||
| MMP3 | Overexpression/activity | M: yes ( | M: uk | |||||||
| MMP8 | Overexpression/activity | M: yes ( | M: uk | |||||||
| MMP9 | Overexpression/activity | M: yes ( | M: uk | |||||||
| MMP13 | Overexpression/activity | M: yes ( | M: uk | |||||||
| Inflammation | IL-1α | Overexpression/activity | M: yes ( | M: uk | ||||||
| IL-1β | Overexpression/activity | M: yes ( | M: uk | |||||||
| IL-6 | Overexpression/activity | M: yes ( | M: uk | |||||||
| IL-8 | Overexpression/activity | M: yes ( | M: uk | |||||||
| TNF-α | Overexpression/activity | M: yes ( | M: uk | |||||||
| 14-3-3 | Overexpression/activity | M: uk | M: uk | |||||||
| Pain | Nerve growth factor | Increase | M: uk | M: uk | ||||||
| Adenosine triphosphate | Increase | M: uk | M: uk | |||||||
| Cyclooxygenase-2, prostaglandin E2 | Overexpression/activity | M: yes ( | M: uk | |||||||
| Substance P | Increase | M: uk | M: uk | |||||||
| Calcitonin gene-related peptide | Increase | M: yes ( | M: uk | |||||||
| Lactic acid | Increase | M: uk | M: uk | |||||||
| Oxidative stress | Advanced glycation end product/receptor for advanced glycation end products | Increase overexpression/activity | M: yes ( | M: uk | ||||||
| Reactive oxygen species, NO | Increase | M: yes ( | M: uk | |||||||
M, meniscus; SF, synovial fluid; uk, unknown.
Figure 3Known and putative molecular hallmarks of painful meniscal pathology. Suggested mechanisms in meniscal pathophysiology are inflammation and oxidative stress that together contribute to degradation of ECM. IL-1, interleukin-1; TNF-α, tumor necrosis factor alpha; IL1R, interleukin-1 receptor; TNFR, TNF receptor; TRAF, TNF receptor-associated factor; IRAK, interleukin receptor-associated kinase; ROS, reactive oxygen species; NO, nitric oxide; SASP, senescence-associated secretory phenotype; AGEs, advanced glycation end products; PM, plasma membrane; ECM, extracellular matrix.